[
    [
        {
            "time": "",
            "original_text": "重慶智飛生物換屆 蔣仁生繼續任董事長 擬使用不超過30億元自有資金進行現金管理",
            "features": {
                "keywords": [
                    "重慶智飛生物",
                    "蔣仁生",
                    "董事長",
                    "30億元",
                    "自有資金",
                    "現金管理"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫療",
                    "生物技術"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "重慶智飛生物換屆 蔣仁生繼續任董事長 擬使用不超過30億元自有資金進行現金管理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "醫藥行業「專精特新」專題報告：走進「新」時代",
            "features": {
                "keywords": [
                    "醫藥行業",
                    "專精特新",
                    "專題報告",
                    "新時代"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "醫療",
                    "製藥"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "醫藥行業「專精特新」專題報告：走進「新」時代",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "雙抗藥物爆發，40多家藥企布局",
            "features": {
                "keywords": [
                    "雙抗藥物",
                    "爆發",
                    "藥企",
                    "布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "醫療",
                    "製藥"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "雙抗藥物爆發，40多家藥企布局",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]